Completed PHASE3 INTERVENTIONAL 2-arm NCT01228734

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (TAILOR)

An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Metastatic Colorectal Cancer

Interventions 5Fluorouracil Cetuximab Folinic Acid Oxaliplatin

Updated 11 times since 2017 Last updated: Jan 16, 2020 Started: Sep 9, 2010 Primary completion: Jan 25, 2016 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Metastatic Colorectal Cancer and is currently completed. Merck KGaA, Darmstadt, Germany leads this study, which shows 11 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3
Mar 2019 — Feb 2020 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Jan 2019 — Mar 2019 [monthly]

Completed PHASE3
Jul 2018 — Jan 2019 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
May 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — May 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Changchun, China , Changsha, Hunan, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , KunMing, Yunnan, China and 7 more locations